Marina Picillo1, Roberto Erro2, Marianna Amboni3, Katia Longo4, Carmine Vitale5, Marcello Moccia6, Angela Pierro7, Sara Scannapieco7, Gabriella Santangelo8, Emanuele Spina6, Giuseppe Orefice6, Paolo Barone9, Maria Teresa Pellecchia7. 1. Department of Neuroscience, Reproductive Sciences and Odontostomatology, Federico II University, Naples, Italy; Center for Neurodegenerative Diseases (CEMAND), Department of Medicine and Surgery, University of Salerno, 84131, Italy. 2. Sobell Department of Motor Neuroscience and Movement Disorders, University College London (UCL) Institute of Neurology, London, United Kingdom. 3. Center for Neurodegenerative Diseases (CEMAND), Department of Medicine and Surgery, University of Salerno, 84131, Italy; IDC Hermitage-Capodimonte, Naples, Italy. 4. IDC Hermitage-Capodimonte, Naples, Italy. 5. IDC Hermitage-Capodimonte, Naples, Italy; University of Naples Parthenope, Naples, Italy. 6. Department of Neuroscience, Reproductive Sciences and Odontostomatology, Federico II University, Naples, Italy. 7. Center for Neurodegenerative Diseases (CEMAND), Department of Medicine and Surgery, University of Salerno, 84131, Italy. 8. Neuropsychology Laboratory, Department of Psychology, Second University of Naples, Caserta, Italy. 9. Center for Neurodegenerative Diseases (CEMAND), Department of Medicine and Surgery, University of Salerno, 84131, Italy. Electronic address: pbarone@unisa.it.
Abstract
BACKGROUND: We recently showed specific sex-related patterns of non motor symptoms (NMS) in early, drug-naïve PD patients. However, to date studies investigating gender-related effects of dopaminergic treatment on NMS in early PD are lacking. METHODS: In the present study, we first report a prospective assessment of gender-related differences in the spectrum of NMS before (baseline) and after starting dopaminergic therapy (2-year follow-up) in a large cohort of newly diagnosed PD patients. Differences in NMS frequency between baseline and follow-up were evaluated by McNemar test. Spearman's rank test was employed to explore interactions between NMS and drug treatment. RESULTS: One-hundred and thirty four PD patients (86M and 48W) were included in the present study. At 2-year follow-up, Sadness/blues presented a significant percentage reduction as compared to baseline in both sexes, while Urgency, Daytime sleepiness, Weight change and Sex drive presented a significant percentage increase only in men. At follow up men complained of a greater number of NMS as compared to women. Occurrence of Weight change was related to therapy in both sexes. Male gender was found to be a risk factor for developing Dribbling and Nocturia, irrespective of therapy and clinical features. CONCLUSIONS: In conclusion, our study showed that mood symptoms improved after the introduction of therapy in both sexes, while men appeared to be more prone to develop some NMS possibly linked to dopaminergic treatment.
BACKGROUND: We recently showed specific sex-related patterns of non motor symptoms (NMS) in early, drug-naïve PDpatients. However, to date studies investigating gender-related effects of dopaminergic treatment on NMS in early PD are lacking. METHODS: In the present study, we first report a prospective assessment of gender-related differences in the spectrum of NMS before (baseline) and after starting dopaminergic therapy (2-year follow-up) in a large cohort of newly diagnosed PDpatients. Differences in NMS frequency between baseline and follow-up were evaluated by McNemar test. Spearman's rank test was employed to explore interactions between NMS and drug treatment. RESULTS: One-hundred and thirty four PDpatients (86M and 48W) were included in the present study. At 2-year follow-up, Sadness/blues presented a significant percentage reduction as compared to baseline in both sexes, while Urgency, Daytime sleepiness, Weight change and Sex drive presented a significant percentage increase only in men. At follow up men complained of a greater number of NMS as compared to women. Occurrence of Weight change was related to therapy in both sexes. Male gender was found to be a risk factor for developing Dribbling and Nocturia, irrespective of therapy and clinical features. CONCLUSIONS: In conclusion, our study showed that mood symptoms improved after the introduction of therapy in both sexes, while men appeared to be more prone to develop some NMS possibly linked to dopaminergic treatment.
Authors: Michelle E Fullard; Dylan P Thibault; Veronica Todaro; Susan Foster; Lori Katz; Robin Morgan; Drew S Kern; Jason M Schwalb; Enrique Urrea Mendoza; Nabila Dahodwala; Lisa Shulman; Allison W Willis Journal: Parkinsonism Relat Disord Date: 2017-12-14 Impact factor: 4.891
Authors: Srishti Shrestha; Freya Kamel; David M Umbach; Laura E Beane Freeman; Stella Koutros; Michael Alavanja; Dale P Sandler; Honglei Chen Journal: PLoS One Date: 2017-09-27 Impact factor: 3.240
Authors: Tanya Simuni; Chelsea Caspell-Garcia; Christopher S Coffey; Daniel Weintraub; Brit Mollenhauer; Shirley Lasch; Caroline M Tanner; Danna Jennings; Karl Kieburtz; Lana M Chahine; Kenneth Marek Journal: J Neurol Neurosurg Psychiatry Date: 2017-10-06 Impact factor: 10.154